Molecular Weight of Hyaluronic Acid Has Major Influence on Its Efficacy and Safety for Viscosupplementation in Hip Osteoarthritis: A Systematic Review and Meta-Analysis
| Autor: | Tsung Lin Cheng, Sung-Yen Lin, Ying-Chun Wang, Chung-Hwan Chen, Cheng-Jung Ho, Chia-Lung Shih, Yen-Zung Wu, Hsuan-Ti Huang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Biomedical Engineering Physical Therapy Sports Therapy and Rehabilitation Bioinformatics Osteoarthritis Hip Viscosupplementation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Intra articular Hyaluronic acid Hip osteoarthritis Immunology and Allergy Medicine Humans Hyaluronic Acid Clinical Research papers Aged 030203 arthritis & rheumatology 030222 orthopedics business.industry Middle Aged Molecular Weight Treatment Outcome chemistry Meta-analysis Female business |
| Zdroj: | Cartilage |
| ISSN: | 1947-6043 |
| Popis: | Background This study aimed to compare the efficacy and safety of intra-articular hyaluronic acid (HA) injection with different molecular weights (MWs) for treating hip osteoarthritis (OA). Methods A systematic literature search for relevant studies was conducted in 3 electronic databases, including PubMed, BMJ Journals, and Cochrane Library, from inception to April 2020. Extracted outcomes included visual analogue scale (VAS) (1, 3, and 6 months), Lequesne index (3 and 6 months), and adverse effects. HAs were classified into low-molecular-weight (LMW), moderate-molecular-weight (MMW), high-molecular-weight (HMW), and ultra-high-molecular-weight (UHMW) groups. Meta-analysis was performed using Review Manager 5.3. Results A total of 15 studies with 614 patients were included. Our meta-analysis showed that the HMW HA group had the best improvement in VAS and Lequesne index compared with other HA groups for all the follow-up visits. Moreover, the HMW group demonstrated significantly better improvement than the other groups in VAS at 6-month follow-up and in Lequesne index at 3- and 6-month follow-ups. Analysis for adverse effects revealed low rates of systemic adverse effects (≤0.6%) in all groups and similar rate of local adverse effects (around 10%) among the groups except for UHMW HA group (37.5%). Conclusion Among different MWs of HA for treating hip OA, HMW HA injection demonstrated the best efficacy for up to 6 months after treatment without increased risk of adverse effects. Further studies with more comprehensive data and a higher level of evidence are required to prove our results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|